Rx Bandz taps Leonid again for non-dilutive capital ahead of FDA filing
What's the deal? Rx BandzDealroom has a profile for this one. Try Dealroom → has closed a third tranche of debt financing from Leonid Capital PartnersDealroom has a profile for this one. Try Dealroom → to fund manufacturing of its MiniJect auto-injector platform ahead of an FDA submission. Financial terms were not disclosed. The New Jersey-based medical device company builds compact auto-injectors designed to deliver medications from the home to the battlefield.
Why now? Rx Bandz expects to submit MiniJect to the FDA in late 2026, a step it calls a significant regulatory milestone. The non-dilutive advance extends its runway through that filing while preserving the option of its current $8 million Series A round.
The re-raise: This is the third tranche under a credit facility Leonid first opened in 2024. Rx Bandz has raised repeatedly against its government contract portfolio — a move chief financial officer Christo described as "a capital efficient way to convert program execution into working capital."
What's the endgame? The company has won over $30 million in US military R&D contracts, with its ketamine and hydromorphone programs advancing to Phase III SBIR contracts with the US Air Force's 711th Human Performance Wing. MiniJect targets battlefield pain management but also has civilian uses, including postpartum haemorrhage, antibiotic treatment, and major depressive disorder.
Rx Bandz is in licensing talks with multiple pharmaceutical companies. "Completion of our Device Master File and submission to the FDA will position MiniJect as an attractive platform for pharmaceutical partners," said chief strategy officer Harsha Murthy.
What could go wrong? As a combination product, MiniJect still needs manufacturing validation, reliability testing, and human factors studies to support its filing. Regulatory approval is not guaranteed, and pharmaceutical partnerships remain in discussion rather than signed.
The signal: Debt tied to federal contracts is emerging as a route for hardware startups to fund capital-intensive work without diluting equity. For Rx Bandz, converting military R&D wins into working capital lets it push toward the FDA while keeping its Series A in reserve.
Read more: EIN Presswire
